Impax Laboratories Inc

Impax Laboratories — Q1 2017 Earnings Presentation

26 slides from Impax Laboratories's earnings presentation, May 10, 2017

  1. Slide 1: First Quarter 2017 Results and Business Update

    1 First Quarter 2017 Results and Business Update May 10, 2017

  2. Slide 2: Cautionary Statement Regarding Forward Looking Statements

    2 Impax Cautionary Statement Regarding Forward Looking Statements "Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995: To the extent any statements made in this presentation contain information that is not historical; these statements are forward-looking in nature and

  3. Slide 3: Presentation Overview

    3 Presentation Overview Paul Bisaro – President & Chief Executive Officer  1Q 2017 Results  Consolidation and Improvement Plan (“CIP”)  Pipeline Update Bryan Reasons – Senior Vice President, Chief Financial Officer  1Q 2017 Financial Review  Capital Structure Paul Bisaro  Updated 2017 Financia

  4. Slide 4: Paul Bisaro, President & CEO

    4 Paul Bisaro President & CEO

  5. Slide 5: 1Q 2017 Results

    5 1Q 2017 Results $226 $198 $184 1Q16 4Q16 1Q17 $64 $37 $32 1Q16 4Q16 1Q17 $0.43 $0.16 $0.11 1Q16 4Q16 1Q17 Revenues $ millions Adjusted EBITDA $ millions Adjusted EPS  Year over year results primarily impacted by significant reduction in sales of diclofenac sodium gel – down $49 million  Solid gr

  6. Slide 6: Post 1Q17 Events

    6 Post 1Q17 Events  April 26 - generic Vytorin® approved  Immediately launched; exceeded expectations on launch acceptance  Competitive multiplayer market Generics Business Update IMS NPA Weekly April 21, 2017 0% 5% 10% 15% 20% 25% 30% Share Growth April 2016 – April 2017 6% 26% 0% 10% 20% 30% 40

  7. Slide 7: Specialty Business Update

    7 • 1Q Albenza revenue impacted by higher mix of government contracting sales and prior year supply issue** • Combined anthelmintic share holding in the 42%- 45% range • Continuing to pursue Managed Medicaid contracting opportunities • 1Q revenue and TRx’s impacted by timing and seasonality • Favora

  8. Slide 8: Consolidation and Improvement Plan

    8 Consolidation and Improvement Plan  Consolidating all of Generic R&D, U.S. manufacturing and packaging operations to Hayward facility  Continuing previously announced closure of Middlesex manufacturing site; now includes closure of the Generic R&D site  Reorganizing certain functions including

  9. Slide 9: Consolidation and Improvement Plan

    9 Consolidation and Improvement Plan Previously Announced Four New Initiatives Identified ~$45M Run-Rate Savings ~$85M Run-Rate Savings • Tech Ops and R&D Restructuring - completed 2015 • Close Philadelphia Packaging Facility - completed 2016 • Close Middlesex Manufacturing – estimated completion mi

  10. Slide 10: Consolidation and Improvement Plan Run-Rate Savings

    10 Previously Announced Initiatives ~45M Run-Rate  Realized ~$20M of cost savings in 2016  Additional $12M by year-end 2017 (which annualizes to $24M)  Full run-rate of ~$45M in 2018 New Initiatives ~$85M Run-Rate  Limited savings impact in 2017  Full run-rate of ~$85M by year-end 2019  Total

  11. Slide 11: Continuing to Expand Pipeline Opportunities

    11 Continuing to Expand Pipeline Opportunities Generic R&D 16 14 6 5 Pending at FDA $17B Under Development $6B Solid Oral Dose Alternative Dose 22 19 # of Potential Products FTF or FTM 9 17 Specialty Pharma R&D Portfolio of 41 Products Current U.S. Brand/Generic Market of $23B IPX203 Carbidopa-Levod

  12. Slide 12: Bryan Reasons, Chief Financial Officer

    12 Bryan Reasons Chief Financial Officer

  13. Slide 13: Generic Division 1Q 2017 Results

    13 Generic Division 1Q 2017 Results Refer to the GAAP to non-GAAP reconciliation tables in the appendix for a reconciliation of non-GAAP results $ millions 1Q 2017 4Q 2016 Change 1Q/4Q 1Q 2016 Change 1Q/1Q GENERIC DIVISION Total Revenues $134.1 $139.2 (4%) $170.1 (21%) GAAP Gross Margin (6%) (127%)

  14. Slide 14: Specialty Pharma Division 1Q 2017 Results

    14 Specialty Pharma Division 1Q 2017 Results Refer to the GAAP to non-GAAP reconciliation tables in the appendix for a reconciliation of non-GAAP results $ millions 1Q 2017 4Q 2016 Change 1Q/4Q 1Q 2016 Change 1Q/1Q SPECIALTY PHARMA DIVISION Total Revenues $50.3 $59.2 (15%) $55.4 (9%) GAAP Gross Marg

  15. Slide 15: Consolidated 1Q 2017 Results

    15 Consolidated 1Q 2017 Results Refer to the GAAP to non-GAAP reconciliation tables in the appendix for a reconciliation of non-GAAP results $ millions, except per share amounts 1Q 2017 4Q 2016 Change 1Q/4Q 1Q 2016 Change 1Q/1Q EBITDA ($30.2) ($234.0) 87% $5.6 (639%) Adjusted EBITDA $31.9 $37.3 (14%

  16. Slide 16: Capital Structure

    16 Capital Structure ($ millions) Cash and Cash Equivalents $ 157 Revolver ($200) $ 0 2022 Convertible Senior Notes 600 Senior Secured Term Loan 340 Total Debt $ 940 Total Net Debt $ 783 Capital Structure as of March 31, 2017 Revised debt covenants provides additional operating flexibility Previous

  17. Slide 17: Paul Bisaro, President & CEO

    17 Paul Bisaro President & CEO

  18. Slide 18: Updated 2017 Financial Guidance Summary

    18 Updated 2017 Financial Guidance Summary Previous Guidance March 1 Updated Guidance May 10** Adjusted Gross Margin as a % of Revenues ~ 47% to 49% No Change Adjusted R&D & Patent Litigation Expense ~ $90M to $95M No Change Adjusted Selling, General & Administrative Expense ~ $190M to $195M No Chan

  19. Slide 19: Path Forward

    19 Path Forward • Impax Generics: Expand & diversify portfolio • Impax Specialty: Focus on differentiated products targeting Movement Disorders and other CNS opportunities Invest for Growth • Continue highest level of Quality • Maintain superior service levels • Deliver differentiated products to ou

  20. Slide 20: Q&A

    20 Q&A

  21. Slide 21: ANDA Pipeline Includes Several Potential High-Value First-to-Market Opportunities

    21 ANDA Pipeline Includes Several Potential High-Value First-to-Market Opportunities Source of sales data: IMS NPS Mar 2017; Pipeline data as of Apr 30, 2017; TA = tentative approval 1 Launched authorized generic in April 2016 2 Assuming final FDA approval, earliest potential launch date/timing base

  22. Slide 22: GAAP to Adjusted Results Reconciliation

    22 GAAP to Adjusted Results Reconciliation The following table reconciles total Company reported cost of revenues to adjusted cost of revenues, adjusted gross profit, adjusted gross margin, adjusted research and development expenses, and adjusted selling, general and administrative expenses. (Unaudi

  23. Slide 23: GAAP to Adjusted Net Income Reconciliation

    23 GAAP to Adjusted Net Income Reconciliation The following table reconciles reported net loss to adjusted net income. (Unaudited, In thousands, except per share and per share data) Refer to the First Quarter 2017 Earnings Release for an explanation of adjusted items. The sum of the individual amoun

  24. Slide 24: GAAP to Adjusted EBITDA Reconciliation

    24 GAAP to Adjusted EBITDA Reconciliation Refer to the First Quarter 2017 Earnings Release for an explanation of adjusted items. The sum of the individual amounts may not equal due to rounding. The following table reconciles reported net loss to adjusted EBITDA. (Unaudited, In thousands) March 31, D

  25. Slide 25: Generic Division GAAP to Adjusted Results Reconciliation

    25 Generic Division GAAP to Adjusted Results Reconciliation The following tables reconcile the Impax Generics Division reported cost of revenues and (Loss) income from operations to adjusted cost of revenues, adjusted gross profit, adjusted gross margin and adjusted operating income. (Unaudited, In

  26. Slide 26: Specialty Pharma Division GAAP to Adjusted Results Reconciliation

    26 Specialty Pharma Division GAAP to Adjusted Results Reconciliation The following tables reconcile the Impax Specialty Pharma Division reported cost of revenues and (Loss) income from operations to adjusted cost of revenues, adjusted gross profit, adjusted gross margin and adjusted income from oper

Impax Laboratories — Q1 2017 Earnings Presentation on 6ix